Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter
This article was originally published in PharmAsia News
Executive Summary
3SBio, the first Chinese biotechnology company to list on NASDAQ, reported strong second-quarter earnings for its lead EPO and thrombopoietin products and is on track to launch a pre-filled syringe EPO product in China by year-end, the firm announced Aug. 8
You may also be interested in...
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
SHANGHAI - China's 3SBio Pharmaceutical and U.S.-based AMAG Pharmaceuticals have entered into a strategic partnership to develop and commercialize AMAG's nanoparticle agent Ferumoxytol in China, the two companies announced May 27
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
SHANGHAI - China's 3SBio Pharmaceutical and U.S.-based AMAG Pharmaceuticals have entered into a strategic partnership to develop and commercialize AMAG's nanoparticle agent Ferumoxytol in China, the two companies announced May 27
3SBio Growth Driven By EPO With Shaky Future
Concerns raised by 3SBio's announcement of development delays for additional indications of its lead product EPIAO (recombinant human erythropoietin injection) are overshadowed by the product's growth potential, according to analysts